GenoMed4All at ASH 2022 New Orleans
Last December some members from GenoMed4All's clinical team travelled all the way to New Orleans for the 64th Annual Meeting and Exposition of the American Society of Hematology.
GenoMed4All was featured there as a showcase of the work currently going on within our use cases. We had the opportunity to present a poster and present our research in an oral presentation. Take a look:
- The foundation of our oral presentation: Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndrome
- The full text making up our poster: Multi-Modal Analysis and Federated Learning Approach for Classification and Personalized Prognostic Assessment in Myeloid Neoplasms
And as a treat, scroll down to see our teammates from Humanitas just having a great time at ASH 2022!
Clinical relevance of clonal hematopoiesis in persons aged ≥80 years
The first official publication for GenoMed4All is out! The article has been published at the Blood journal from the American Society of Hematology, under the title Clinical relevance of clonal hematopoiesis in the oldest-old population. The focus is on the general elderly population (80 year-olds and above) and the paper aims to correlate genomic profiles to the risk of developing MDS (Myelodysplastic Syndromes) and other haematological malignancies.
Abstract
Clonal hematopoiesis of indeterminate potential (CHIP) is associated with increased risk of cancers and inflammation-related diseases. This phenomenon becomes common in persons aged ≥80 years, in whom the implications of CHIP are not well defined. We performed a mutational screening in 1794 persons aged ≥80 years and investigated the relationships between CHIP and associated pathologies.
